Association of acute interstitial nephritis with nivolumab in renal cell carcinoma: A case report

Recently, a number of innovative anticancer agents such us the programmed death 1 (PD-1) immune checkpoint inhibitors have been developed. Nevertheless, this type of immunotherapy may be associated with immune-related adverse events whose pathophysiology is considered similar to those found in autoi...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of nephrology 2021-05, Vol.31 (3), p.303-306
Main Authors: Noto-Kadou-Kaza, Befa, Desbuissons, Geoffroy, Isnard, Corinne
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Cancer
Carcinoma
Care and treatment
Case Report
Chemotherapy
Immunotherapy
Metastasis
Nephritis
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, a number of innovative anticancer agents such us the programmed death 1 (PD-1) immune checkpoint inhibitors have been developed. Nevertheless, this type of immunotherapy may be associated with immune-related adverse events whose pathophysiology is considered similar to those found in autoimmune diseases such as nephritis. We report the case of a 71-year-old female with metastatic renal carcinoma who underwent nephrectomy. After three lines of other chemotherapies (VEGF and mTOR inhibitors), the patient was treated by nivolumab (3 mg/kg) for 4 months and developed acute kidney injury 16 weeks after initiating this immunotherapy. Kidney biopsy displayed a diffuse extensive interstitial inflammation associated with moderate interstitial edema. The discontinuation of nivolumab and the administration of prednisone (at 1 mg/kg and tapered over 3 months) was an effective treatment of the interstitial edema and led to the recovery of the kidney function.
ISSN:0971-4065
1998-3662
DOI:10.4103/ijn.IJN_62_20